Hyperbaric oxygen therapy is one of the older, better-established medical treatments in the modern hospital system. It also happens to be one of the most oversold interventions in the wellness industry. Both statements are true, and untangling them is worth doing carefully because the price tag on a home chamber has climbed into the same range as a used car.
Vyvata does not carry HBOT chambers. There is no product to sell you at the end of this article. What we do have is a category where the clinical evidence and the marketing claims have diverged enough that a plain reading of the literature is useful on its own.
What HBOT actually is
Hyperbaric oxygen therapy places a patient inside a sealed chamber at pressure above atmospheric, breathing 100 percent oxygen. The combination of elevated pressure and elevated inspired oxygen fraction dissolves substantially more oxygen into the blood plasma than normal breathing allows. Where hemoglobin is normally near-saturated at sea level, plasma oxygen content climbs by a factor of ten or more under clinical HBOT conditions. That plasma-dissolved oxygen can perfuse tissues that hemoglobin-bound oxygen cannot reach efficiently — a poorly-vascularized wound bed, a damaged brain area, an infection where anaerobic organisms dominate.
Clinical HBOT chambers operate at 2.0 to 2.5 atmospheres absolute (ATA) — roughly equivalent to being 33 to 50 feet underwater — and deliver 100 percent oxygen through a mask, hood, or the ambient chamber. Sessions typically run 60 to 120 minutes and are prescribed in multi-session courses (often 20 to 40) supervised by hyperbaric physicians.
Soft-shell home chambers — the kind marketed to wellness consumers — operate at 1.3 ATA. That is not a small difference. It is the difference the FDA and every clinical hyperbaric society uses to distinguish clinical HBOT from what is called mild hyperbaric therapy or mHBOT. Both are real interventions; they are not the same intervention.
The FDA-approved indications
The Undersea and Hyperbaric Medical Society maintains a list of approved indications that the FDA and CMS have historically recognized for reimbursement. As of the current edition there are thirteen. They are unglamorous, well-studied, and consistent with the biological mechanism.
- Air or gas embolism.
- Carbon monoxide poisoning, including CO complicated by cyanide poisoning.
- Clostridial myositis and myonecrosis (gas gangrene).
- Crush injury, compartment syndrome, and other acute traumatic ischemias.
- Decompression sickness.
- Enhancement of healing in selected problem wounds, including diabetic foot ulcers meeting specific criteria.
- Severe anemia when transfusion is not possible.
- Intracranial abscess.
- Necrotizing soft tissue infections.
- Refractory osteomyelitis.
- Delayed radiation injury (soft tissue and bony necrosis).
- Compromised skin grafts and flaps.
- Acute thermal burn injury and idiopathic sudden sensorineural hearing loss.
Read those indications and note what they share. They are conditions where oxygen delivery to a specific tissue is the rate-limiting step to healing, or where oxygen is directly antibacterial against the pathogen, or where dissolved gas physics matters (embolism, decompression sickness). The mechanism is doing recognizable work.
Read what is not on that list. General anti-aging. Cognitive enhancement in healthy adults. Fatigue. Autoimmune disease. Autism. Long COVID. Athletic performance in healthy people. Post-workout recovery. Every one of those has been marketed by at least one wellness clinic. None of them is FDA-approved. That does not automatically mean the treatment does not help — but the evidence bar for the marketing claims is much lower than for the approved indications, and the price tag is much higher.
The Efrati work: real, worth citing, worth caveating
The wellness-adjacent HBOT case rests heavily on the work of Shai Efrati and colleagues at Tel Aviv University. It deserves specific attention.
Efrati's group has published a series of trials, mostly in the 2010s and early 2020s, applying long courses of HBOT (typically 60 sessions at 2.0 ATA) to conditions the FDA does not cover: post-concussive syndrome and mild traumatic brain injury, post-stroke cognitive impairment, and — most publicized — apparent biological aging markers in healthy older adults. The 2020 Aging paper by Hachmo, Efrati, and colleagues reported telomere lengthening and reductions in senescent cell counts in older adults after 60 HBOT sessions. That is a striking claim and it generated a large press response.
The caveats:
- Small sample sizes. Most of the Efrati trials enroll fewer than 100 participants. Effect sizes look large in small trials and shrink in replications.
- Sham HBOT is hard to blind. Participants feel pressure changes. Sham arms in this literature are structurally weaker than sham arms in drug trials.
- Single-group replication is thin. Most of the striking findings come from one research group at one institution. Independent replication in other populations at other institutions is limited.
- The protocol is 60 sessions at clinical pressure. Not five sessions in a soft-shell chamber. Anyone citing Efrati to justify home mHBOT is misrepresenting the dose the studies used.
None of this makes Efrati's work uninteresting. It is a real line of research that has broken new ground and deserves to be replicated. It is not evidence that HBOT is a proven anti-aging intervention. Treat it as a hypothesis under active investigation, not as a settled result.
Why 1.3 ATA is not 2.0 ATA
The soft-shell home chamber market has grown by presenting mHBOT as a home-accessible version of clinical HBOT. Physiologically, they are different interventions.
At 1.3 ATA breathing room air (21 percent oxygen), the fraction of inspired oxygen and the ambient pressure combine to raise plasma-dissolved oxygen modestly above baseline. If you add supplemental oxygen through a concentrator — which not all mHBOT setups include — you can push closer to a physiologically meaningful oxygen delivery, but you are still at a fraction of clinical HBOT delivery.
At 2.0 to 2.5 ATA breathing 100 percent oxygen, plasma-dissolved oxygen rises by roughly an order of magnitude above sea-level baseline. That is the delivery level that heals a refractory wound, treats decompression sickness, or drives the effects Efrati studied. The dose-response for the mechanisms that HBOT is thought to activate — nitric oxide signaling, HIF-1a induction, stem cell mobilization, angiogenesis — is not linear at low pressures. Below a threshold, you get very little of the biological effect the pressure is meant to produce.
The honest way to think about mHBOT: it is a lower-dose intervention with substantially less evidence than clinical HBOT. Whether the lower dose is a scaled-down version of the same effect or a qualitatively different exposure that does very little at all is an open question. Do not spend clinical-HBOT money on mHBOT expectations.
The safety concerns that get glossed over
The wellness marketing usually presents HBOT as effectively risk-free. The clinical documentation is more careful, because there are real risks that scale with pressure, oxygen concentration, and session duration.
Barotrauma
The most common adverse event. Middle ear barotrauma occurs when the eustachian tubes cannot equalize the pressure change fast enough during compression or decompression. Ranges from mild ear pain to tympanic membrane rupture. Sinuses and dental fillings can also produce barotrauma symptoms. Pulmonary barotrauma is rarer but more serious: a lung with obstructed airflow (from a bleb, a cyst, or bronchospasm) can rupture on decompression. Clinical HBOT programs screen patients with chest imaging before treatment. Consumer setups typically do not.
Central nervous system oxygen toxicity
Prolonged exposure to high partial pressures of oxygen can produce seizures. The classic "Paul Bert effect" is well documented in diving and in HBOT. Clinical protocols include supervised "air breaks" every 20 to 25 minutes at 2.5 ATA to reset the CNS oxygen dose. This is one of the reasons unsupervised long sessions at clinical pressures are unwise.
Fire risk
An oxygen-enriched enclosure is a fire hazard on a scale the general public underestimates. Static discharge, a spark from an electronic device, or an oil-contaminated material can start a fire in an atmosphere where fires spread far faster than in normal air. The Apollo 1 accident is the textbook case. Clinical HBOT chambers enforce strict material and clothing restrictions and prohibit electronics. Home users routinely bring phones and books inside. If you use any oxygen-enriched chamber at home, take the fire risk seriously.
Contraindications
Untreated pneumothorax is an absolute contraindication — pressure can convert it to a tension pneumothorax on decompression. Certain chemotherapy drugs (bleomycin especially) interact catastrophically with high-pressure oxygen. Some ear surgeries, some seizure disorders, and some claustrophobic reactions all warrant discussion with a physician before HBOT.
The price gap
Clinical HBOT sessions run roughly $250 to $600 per session in the United States, often covered by insurance when the indication is on the approved list. A course of 40 sessions therefore runs into five figures with insurance handling most of it.
Soft-shell home chambers, at 1.3 ATA, run roughly $5,000 to $20,000 to purchase and are essentially never covered by insurance because they do not deliver clinical HBOT. Hard-shell home chambers rated to clinical pressures run $50,000 to $200,000 and require dedicated space, power, and often a technician to operate safely.
The wellness clinic market splits the difference: cash-pay sessions at 1.5 to 2.0 ATA typically cost $100 to $250 per session and are not covered by insurance for wellness-oriented use cases. If you were running a full Efrati-style protocol at a wellness clinic — 60 sessions at 2.0 ATA — the total bill would be $6,000 to $15,000.
Who might reasonably use HBOT, and how
An honest reading of the evidence supports HBOT for the approved indications when prescribed and supervised by hyperbaric medicine specialists. Full stop. That is the tier of use where the risk-benefit and cost-benefit ratios have been established.
Beyond the approved list, an honest reading supports a much narrower proposition: HBOT at clinical pressures may have real effects on brain injury recovery and possibly on aspects of biological aging, but the evidence is early, largely single-group, and involves multi-session protocols the wellness market rarely delivers accurately.
If you are considering HBOT outside the approved indications, the reasonable questions to ask a clinic are:
- What pressure will the sessions actually run at, and how is that pressure verified?
- Who is the supervising physician and what is their hyperbaric medicine training?
- Do you follow a written protocol with air breaks and monitored oxygen limits?
- What are the fire-safety and pre-treatment screening procedures?
- What is the specific evidence base for the indication you are treating me for?
A clinic that answers those questions well is different from one that cites Efrati at you and hands you a soft-shell chamber to lie in.
What the wellness industry gets wrong
The most common overreaches to be alert for.
- Presenting mHBOT as clinical HBOT. Marketing copy that cites 2.0 ATA studies while operating at 1.3 ATA is misrepresenting the dose.
- Single-session claims. No indication in the peer-reviewed literature responds meaningfully to one session. If a chamber is being marketed on same-day results, either the results are a placebo response to novelty and rest, or the marketing is loose.
- Universal fatigue and brain fog claims. These endpoints do not respond meaningfully to HBOT in the published trials in healthy people, and the mechanism is not what an oxygen-and-pressure intervention is best suited to.
- Home chambers as anti-aging devices. The Efrati aging paper used 60 sessions at 2.0 ATA. Home soft-shell chambers cannot replicate that protocol at any session count.
The honest bottom line
HBOT is a real medical treatment with a well-documented mechanism, a specific list of approved indications, and a set of well-characterized risks that get downplayed in the wellness market. Outside the approved list, the evidence for benefit is early and mostly comes from one research group at one institution — worth watching, not worth taking as established fact yet. Soft-shell mHBOT chambers are not clinical HBOT and should not be priced or discussed as if they were. If you are being sold HBOT for a wellness indication, the fair reading is: the intervention might do something, we do not yet know at what dose, and the amount you are being asked to spend is large relative to the strength of the current evidence.
The reason Vyvata does not carry HBOT chambers is straightforward. A category where a $10,000 home device sits at a pressure the clinical literature does not support, where the strongest evidence points to a treatment protocol home hardware cannot deliver safely, and where the safety documentation is asymmetrically underemphasized in consumer marketing is not a category we can honestly recommend hardware in. If HBOT interests you, start with the approved-indication side of the conversation and the peer-reviewed literature. The store aisle is not where this decision lives.
